REGN vs WAT: fair value comparison
Regeneron Pharmaceuticals, Inc. and Waters Corporation · Updated 2026-09-12
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, WAT currently sits closer to the top of our discount ranking. REGN carries the stronger quality grade.
| REGN | WAT | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $781.49 | $408.34 |
| 12-month range | $600.66–$823.82 | $299.89–$405.84 |
| Sector rank | #66 of 113 Healthcare | #61 of 113 Healthcare |
| Quality grade | A | B |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: REGN fair value analysis · WAT fair value analysis